No Data
No Data
[Brokerage Focus] China Post Securities maintains a 'buy' rating on Consun Pharma (01681), stating that the volume-based pricing model in the first half of the year has been effective, and the company is expected to continue its growth momentum in the sec
Jingu Wealth Information | China Post Securities issued a research report, stating that Consun Pharma (01681) achieved revenue of 1.269 billion yuan in H1 2024 (+13.30%); realized a net income attributable to the parent company of 0.4 billion yuan (+14.91%); gross margin 74.69%, flat year-on-year; good expense control, sales expense ratio of 32.47% (+0.14pct), absolute value reduction of management expenses, promoting a 1.59pct decrease in management expense ratio to 10.62%; net margin attributable to the parent company 31.51% (+0.44pct), with a stable and upward profit capability. The bank continued to point out that in the first half of 2024
Potential Upside For Consun Pharmaceutical Group Limited (HKG:1681) Not Without Risk
Consun Pharma Announces Executive Reshuffle
Consun Pharma (01681.HK): Gao Haien appointed as company secretary and authorized representative.
On August 22nd, Consun Pharma (01681.HK) announced that Qiu Zhiming has resigned as the company's company secretary and authorized representative, effective from August 22nd, 2024. Gao Haie has been appointed as the new company secretary and authorized representative, effective from August 22nd, 2024.
Hong Kong stock market anomaly | Consun Pharma (01681) rose more than 6% after the performance, with a 14.9% increase in net profit to 0.4 billion RMB in the first half of the year and an interim dividend of 0.3 Hong Kong dollars.
Consun Pharma (01681) rose more than 6% after the performance, up 6.06% as of the time of publication, at 5.95 Hong Kong dollars, with a turnover of 38.032 million Hong Kong dollars.
Consun Pharma (01681) will distribute a interim dividend of HKD 0.3 per share on September 20th.
Consun Pharma (01681) announced that the company will distribute a mid-term dividend of HKD 0 per share on September 20, 2024.
No Data